Table 1.
Targeted Immunotherapies and the autoimmune conditions.
| Targeted therapy | Biologic agent | Autoimmune conditions |
|---|---|---|
| Anti CD20 targeted therapy | Rituximab | RA, AHA, ITP, TTP, SLE, RD, WG, ABS, GHD allogeneic transplantation |
| Anti IL 6 targeted therapy | Tocilizumab | RA, SLE, SS, AHA, Systemic juvenile idiopathic arthritis, Acquired hemophilia A |
| Anti TNF targeted therapy | Etanercept | Juvenile RA, RA, AS, Plaque psoriasis, Psoriatic arthritis |
| Adalimumab | RA, AS, CD, Psoriatic arthritis | |
| Golimumab | RA, UC | |
| Certolizumab pegol | CD, Psoriatic arthritis | |
| Infliximab | RA, AS, CD, UC, Psoriatic arthritis, Chronic plaque psoriasis | |
| Anti Th 17 A targeted therapy | Secukinumab | RA, AS, Psoriasis, Psoriatic arthritis |
| Anti CD22 targeted therapy | Epratuzumab | SLE, Primary SjS |
RA- Rheumatoid arthritis, AHA- Autoimmune haemolytic anaemia, ITP-Immune thrombocytopenic purpura,TTP-Thrombotic thrombocytopenic purpura, SLE-Systemic lupus erythematosus, RD- Refractory dermatomyositis, WG-Wegener’s granulomatosis, ABS- Autoimmune bullous diseases of skin, GHD-Graft-versus-host disease, SS- Systemic sclerosis, CD- Crohn’s disease, AS- Ankylosing spondylitis, UC- Ulcerative colitis, SjS- Sjogren syndrome.